Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Onconetix, Inc.ONCO · Entity 8471 | Interim CEO, CSO | December 20, 2024 | January 22, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Onconetix, Inc.
Report date December 20, 2024 · Filed January 22, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 673,365 |
Reported balance
After 2024-12-20 transaction · row 1
1 source rowRow 1 · 2024-12-20 · Grant · Acquired 177,462 · Balance 673,365 F1: Represents shares of Common Stock of the Issuer issuable upon settlement of Restricted Stock Units. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of Common Stock of the Issuer issuable upon settlement of Restricted Stock Units.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 20, 2024 Filed Jan 22, 2025 16:15 UTC | Onconetix, Inc. ONCO · Entity 8471 | GrantCommon Stock | 177,462 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-25-005492 · ownership.xml · nonDerivative · entry 1 Schiess Ralph · CIK 0002006201 · Interim CEO, CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 673,365 F1 · shares: Represents shares of Common Stock of the Issuer issuable upon settlement of Restricted Stock Units. Read SEC document |
| September 24, 2024 Filed Sep 26, 2024 16:05 UTC | Onconetix, Inc. ONCO · Entity 8471 | GrantCommon Stock | 489,160 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-24-082238 · ownership.xml · nonDerivative · entry 1 Schiess Ralph · CIK 0002006201 · Interim CEO & CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 495,903 F1 · kind: Represents shares of common stock of the Issuer issued to the Reporting Person upon automatic conversion of Series B preferred stock ("Preferred Shares") of the Issuer, in accordance with the Certificate of Designation for the Preferred Shares. F1 · price: Represents shares of common stock of the Issuer issued to the Reporting Person upon automatic conversion of Series B preferred stock ("Preferred Shares") of the Issuer, in accordance with the Certificate of Designation for the Preferred Shares. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.